CompletedNot Applicable

Cerebrotendinous Xanthomatosis (CTX) Prevalence Study

United States442 participantsStarted 2015-09

Plain-language summary

Iiopathic bilateral cataracts occur in many children with Cerebrotendinous Xanthomatosis (CTX) so the opportunity to use contact with health care providers in connection with pediatric cataract evaluation and treatment is a promising avenue for disease detection and prevention.

Who can participate

Age range2 Years – 21 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. The patient has a diagnosis of idiopathic bilateral cataracts
✓. Between the ages of 2 to 21 years at the time of diagnosis

Exclusion criteria

✕. The patient has a diagnosis of cataracts with known etiology other than CTX
✕. The patient has a diagnosis of CTX
✕. The patient has cataracts caused by cataractogenic treatments
✕. The patient has taken or is currently taking cholic acid or chenodeoxycholic acid
✕. The patient has participated in an interventional clinical trial in the past 30 days
✕. The patient and/or their parent/legal guardian, in the opinion of the Investigator, is unable to adhere to the requirements of the study

What they're measuring

Number of Participants Who Had Positive Genetic Test Results

Timeframe: At genetic testing

Trial details

NCT IDNCT02638220

SponsorTravere Therapeutics, Inc.

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2021-02-19

Results submitted2023-06-08

View on ClinicalTrials.gov More Cerebrotendinous Xanthomatosis (CTX) trials